The global plasma protein therapeutics market was valued at $26.5 billion in 2021, and is projected to reach $44.3 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.
Plasma protein therapeutics are a subcategory of biopharmaceuticals made from human blood plasma and are used to treat a range of diseases. Natural components called plasma proteins are present in blood and are essential for preserving good health and preventing disease. Various compounds, such as immunoglobulin, clotting factors, albumin, and other specialized plasma proteins, are included in the category of plasma protein therapies. These medicines are used to treat a range of illnesses, such as Kawasaki disease, immunological deficiencies, blood problems, liver ailments, autoimmune diseases, and neurological disorders such as chronic polyneuropathy.
The market for plasma protein therapeutics is driven by factors such as an increase in the prevalence of chronic diseases with unmet needs, rise in an aging population, and advancements in protein therapies technology and rise in R&D in the plasma protein field. The demand for these products is expected to continue to grow due to an increase in the incidence of chronic immunological diseases, particularly in developing countries. In addition, new product development and new product approval are significant drivers of growth for the plasma protein therapeutics market. For an instance, in February 2020 CSL Behring announced that the U.S. Food and Drug Administration (FDA) has granted Privigenne (Immune Globulin Intravenous (Human),10% Liquid) orphan-drug designation as an investigational therapy in the treatment of Systemic Sclerosis (SSc). Moreover, market growth is also driven by market participants forming strategic alliances and working together with universities, research facilities, and other organizations. Furthermore, companies are acquiring smaller players to expand their product portfolio, increase their market presence, and gain access to new markets. Thus, the rise in adoption of strategies by key market players, such as mergers and acquisitions, product innovation, and expanding distribution networks, is driving the growth of the plasma protein therapeutics market.
There is an increase in the demand for plasma protein therapeutics as patients and medical professionals prefer more effective and specific treatments for a variety of diseases, including immunological disorders and autoimmune disorders. They offer a variety of advantages over traditional treatment, including improved efficacy, fewer side effects, and the ability to target specific disease-related molecules.
In addition, plasma protein therapeutics have been gaining significant attention in recent years due to their potential to treat a wide range of medical conditions, including immune disorders, and bleeding disorders. Rise in demand for advanced therapeutics, as patients and healthcare professionals look for more effective and focused therapies for various diseases also drives the market growth.
However, stringent guidelines for storage, testing, and collection from donors, of plasma is expected to restrain the growth of the plasma protein therapeutics market. On the other hand, development of targeted plasma protein therapies that can be used to treat specific disorders has been made possible by modifications in analytical and diagnostic technologies. Research and technological advancements have made it possible to create novel plasma protein therapies that improve patient outcomes. Thus, technological advancements in the field of plasma protein therapeutics offer a significant opportunity for market growth.
The plasma protein therapeutics market is segmented into product type, application, end user and region. By product type, the market is categorized into immunoglobulin, albumin, plasma factor derived VIII, and others. By application, the market is segregated into hemophilia, idiopathic thrombocytopenic purpura , primary immunodeficiency, and others. By end user, the market is categorized into hospitals and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global plasma protein therapeutics market are ADMA Biologics Inc, Bayer AG, Bio products laboratory, Baxter International, CSL Limited, Grifsols, Kedrion SpA, Octapharma USA Inc, Taibang Biological Group Co. Ltd, and Takeda Pharmaceutical Company Limited.
Plasma protein therapeutics are a subcategory of biopharmaceuticals made from human blood plasma and are used to treat a range of diseases. Natural components called plasma proteins are present in blood and are essential for preserving good health and preventing disease. Various compounds, such as immunoglobulin, clotting factors, albumin, and other specialized plasma proteins, are included in the category of plasma protein therapies. These medicines are used to treat a range of illnesses, such as Kawasaki disease, immunological deficiencies, blood problems, liver ailments, autoimmune diseases, and neurological disorders such as chronic polyneuropathy.
The market for plasma protein therapeutics is driven by factors such as an increase in the prevalence of chronic diseases with unmet needs, rise in an aging population, and advancements in protein therapies technology and rise in R&D in the plasma protein field. The demand for these products is expected to continue to grow due to an increase in the incidence of chronic immunological diseases, particularly in developing countries. In addition, new product development and new product approval are significant drivers of growth for the plasma protein therapeutics market. For an instance, in February 2020 CSL Behring announced that the U.S. Food and Drug Administration (FDA) has granted Privigenne (Immune Globulin Intravenous (Human),10% Liquid) orphan-drug designation as an investigational therapy in the treatment of Systemic Sclerosis (SSc). Moreover, market growth is also driven by market participants forming strategic alliances and working together with universities, research facilities, and other organizations. Furthermore, companies are acquiring smaller players to expand their product portfolio, increase their market presence, and gain access to new markets. Thus, the rise in adoption of strategies by key market players, such as mergers and acquisitions, product innovation, and expanding distribution networks, is driving the growth of the plasma protein therapeutics market.
There is an increase in the demand for plasma protein therapeutics as patients and medical professionals prefer more effective and specific treatments for a variety of diseases, including immunological disorders and autoimmune disorders. They offer a variety of advantages over traditional treatment, including improved efficacy, fewer side effects, and the ability to target specific disease-related molecules.
In addition, plasma protein therapeutics have been gaining significant attention in recent years due to their potential to treat a wide range of medical conditions, including immune disorders, and bleeding disorders. Rise in demand for advanced therapeutics, as patients and healthcare professionals look for more effective and focused therapies for various diseases also drives the market growth.
However, stringent guidelines for storage, testing, and collection from donors, of plasma is expected to restrain the growth of the plasma protein therapeutics market. On the other hand, development of targeted plasma protein therapies that can be used to treat specific disorders has been made possible by modifications in analytical and diagnostic technologies. Research and technological advancements have made it possible to create novel plasma protein therapies that improve patient outcomes. Thus, technological advancements in the field of plasma protein therapeutics offer a significant opportunity for market growth.
The plasma protein therapeutics market is segmented into product type, application, end user and region. By product type, the market is categorized into immunoglobulin, albumin, plasma factor derived VIII, and others. By application, the market is segregated into hemophilia, idiopathic thrombocytopenic purpura , primary immunodeficiency, and others. By end user, the market is categorized into hospitals and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global plasma protein therapeutics market are ADMA Biologics Inc, Bayer AG, Bio products laboratory, Baxter International, CSL Limited, Grifsols, Kedrion SpA, Octapharma USA Inc, Taibang Biological Group Co. Ltd, and Takeda Pharmaceutical Company Limited.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the plasma protein therapeutics market analysis from 2021 to 2031 to identify the prevailing plasma protein therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the plasma protein therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global plasma protein therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product type
- Immunoglobulin
- Albumin
- Plasma derived factor VIII
- Others
By Application
- Hemophilia
- Idiopathic thrombocytopenic purpura
- Primary immunodeficiency disorder
- Others
By End user
- Hospitals
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Bayer AG
- Bio Products Laboratory Ltd
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Baxter International Inc.
- Kedrion, SpA
- Octapharma AG
- CSL Limited
- ADMA Biologics Inc
- Taibang Biological Group Co., Ltd
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: PLASMA PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE
CHAPTER 5: PLASMA PROTEIN THERAPEUTICS MARKET, BY APPLICATION
CHAPTER 6: PLASMA PROTEIN THERAPEUTICS MARKET, BY END USER
CHAPTER 7: PLASMA PROTEIN THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Bayer AG
- Bio Products Laboratory Ltd
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Baxter International Inc.
- Kedrion, SpA
- Octapharma AG
- CSL Limited
- ADMA Biologics Inc
- Taibang Biological Group Co., Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
